By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics today said it has completed its $80 million purchase of Rules-Based Medicine.

RBM will remain based in Austin, Texas and will operate as a wholly owned subsidiary of Myriad. RBM discovers biomarkers for pharmaceutical and biotechnology firms using its multiplex immunoassay technology. It will continue its collaborations with pharma partners in companion diagnostic discovery and carry out internal research projects, Myriad said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.